Phase I dose-escalation study of oral administration of S 78454 given with a fixed dose infusion of doxorubicin administered weekly 3 out of 4 weeks in patients with solid tumour
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Abexinostat (Primary) ; Doxorubicin
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 15 Nov 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 29 Sep 2013 New trial record